Validation of Living with Chronic Illness Scale in a Type 2 Diabetes Mellitus population

Jorge Caro-Bautista  
Junta de Andalucia Servicio Andaluz de Salud

Carmen Rodríguez-Blazquez  
Instituto de Salud Carlos III

David Perez-Manchon  
Universidad Camilo Jose Cela

Eva Timonet  
Hospital Costa del Sol

Gloria Carvajal  
Universidad de La Sabana

Alejandra Fuentes-Ramirez  
Universidad de La Sabana

Silvia Corchon  
Universitat de Valencia

Marta Aranda  
Hospital Costa del Sol

Leire Ambrosio (✉ lambrosio@unav.es)  
Universidad de Navarra  https://orcid.org/0000-0002-9450-7210

Research

Keywords: Long-term condition, type 2 diabetes mellitus, chronic illness, study validation, COSMIN

DOI: https://doi.org/10.21203/rs.3.rs-42004/v2

License: 🎁 This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Background: Worldwide, type 2 diabetes mellitus (T2DM) is one of the most prevalent chronic diseases and one of those producing greatest impact on patients’ day-to-day quality of life. Our study aim is to validate the “Living with Chronic Illness Scale” for a Spanish-speaking T2DM population.

Methods: In this observational, international, cross-sectional study, 582 persons with T2DM were recruited in primary care and outpatient hospital consultations, in Spain and Colombia, during the period from May 2018 to June 2019. The properties analysed were feasibility/acceptability, internal consistency, reliability, precision and (structural) content-construct validity including confirmatory factor analysis (CFA). The COSMIN checklist was used to assess the methodological/psychometric quality of the instrument.

Results: The scale had an adequate internal consistency and test retest reliability (Cronbach’s alpha = 0.90; intraclass correlation coefficient = 0.96, respectively). In addition, the instrument is precise (standard error of measurement = 3.34, with values <½SD = 8.52) and correlates positively with social support (DUFSS) ($r_s$ = 0.56), quality of life (WHOQOL) ($r_s$ = 0.51-0.30) and satisfaction (SLS-6) ($r_s$ = 0.50-0.38). The CFA supported the 5-domains structure, but a 23-item version showed better fit: $\text{CMIN/df} = 3.11$; goodness of fit index= 0.91; comparative fit index= 0.91 and root mean square error of approximation = 0.06 (90% confidence interval, 0.06-0.07). The COSMIN checklist is favourable for all the properties analysed, although weaknesses are detected for content validity.

Conclusions: “Living with T2DM” (LW-T2DM) is a valid, reliable and accurate instrument for use in clinical practice to determine how a person’s life is affected by the presence of diabetes. This instrument correlates well with the associated constructs of social support, quality of life and satisfaction. Additional research is needed to determine how well the questionnaire structure performs when robust factor analysis methods are applied.

Background

Human life expectancy has increased sharply during the last century, but in consequence chronic disease is more prevalent and patients are living longer with ill health [1]. Diabetes mellitus (DM) is one of the non-communicable diseases that most prejudices patients’ quality of life, and impacts directly on daily routines. In 2017, according to the International Diabetes Federation (IDF), 451 million people had DM, and this figure is expected to rise to 693 million by 2045. In the same year, five million deaths were attributed to DM, and worldwide 850 billion US dollars were spent on managing the disease [2]. The costs arising from DM are mainly due to the associated complications, chief among which are ischemic heart disease, stroke, diabetic foot and diabetic nephropathy. Socioeconomic factors such as gender, age, education, type of health insurance and the time of evolution since diagnosis are significantly associated with disease outcomes [3].

The impact of DM is not only physical but also psychosocial, as the disease requires comprehensive involvement by healthcare services, which must focus both on clinical symptoms and on how the patient
copes with the disease. In this field, organisations such as the European Association for the Study of Diabetes and the American Diabetes Association recommend that persons with type 2 diabetes mellitus (T2DM) should seek to achieve self-management on the basis of shared decision-making and on lifestyle modification [4].

Patients and healthcare providers do not always coincide in their perceptions of the disease, and therefore it is crucial to identify patients’ needs to ensure that appropriate clinical care is received. From this perspective, and in accordance with the steps outlined in Rodgers’ evolutionary concept analysis [5], we may consider the goal of “living with chronic illness”, which has been defined as “a complex, dynamic, cyclical and multidimensional process with the final desired target being to achieve positive living” [6]. Various instruments have been proposed to measure this or other concepts associated with managing chronicity. Some have evaluated specific constructs: for instance, the Minnesota Living with Heart Failure Questionnaire (MLHFQ) [7] and the Living with Chronic Obstructive Pulmonary Disease Questionnaire (LCOPD) [8] both address the patient’s quality of life; the Chronic Pain Acceptance Questionnaire (CPAQ) [9] focuses on acceptance of the process; Brief-COPE [10] considers how the patient copes with the situation. Other considerations are taken into account in the Diabetes Self-Management Questionnaire (DSMQ) [11] and the Psychosocial Adjustment to Illness Scale (PAIS) [12]. However, none of these approaches are based on a perspective that is sufficiently wide ranging to measure this phenomenon in all its complexity [13].

However, one recently-developed scale addresses the concept of “living with chronic illness”, incorporating a broad spectrum of attributes, including acceptance, coping, self-management, integration and adaptation [6]. This scale, derived from the questionnaire “Living with Chronic Illness” (in Spanish, EC-PC) includes 26 items spanning the above-mentioned dimensions. The EC-PC scale has been validated in a population with Parkinson's disease and has adequate psychometric properties [14]. Its acceptability was later evaluated in a pilot study for other populations (with T2DM, heart failure -HF-, chronic obstructive pulmonary disease -COPD- or osteoarthritis), which showed that the instrument was viable and presented acceptable preliminary levels of validity [15]. The validation of this instrument for persons with T2DM will make it possible to identify the factors that determine whether a patient is living more or less acceptably with the disease, thus providing clinicians with valuable information enabling them to apply focused interventions.

**Methods**

**Design**

An observational, international and cross-sectional study (one point-in-time evaluation, with retest) was carried out. This study is part of a macro research project with the general aim to achieve a unique and international self-reported scale to evaluate the process of living with one or more than one long term condition (LTC), as T2DM, rheumatoid and osteoarthritis, chronic kidney disease, chronic obstructive pulmonary disease, chronic heart failure, high blood pressure, and Parkinson's disease. In particular, this
is study was focus in the validation study of people living with T2DM in a Spanish-speaking population which is part of a chain validation studies carried out in different LTCs and countries (Spain, South America, UK).

Sample, sampling and sample size

A consecutive cases sampling [16,17] was applied to participant identification.

The sample was composed by people living with T2DM from different primary and secondary healthcare centres and community groups from Spain and Colombia. Inclusion criteria were a) patients with T2DM diagnosis made by an endocrinology or General Practitioner (GP), in any stage of the disease; b) Colombian or Spanish nationality; c) able to read and understand properly the questionnaires; and d) non-hospitalized patient at the moment of the study. Exclusion criteria were a) patients with cognitive deterioration, acute disorder and/or pharmacological effects that potentially could distort the objective of the study; b) refusal to participate in the study and c) not meeting established inclusion criteria.

Sample size was calculated according to the model proposed by MacCallum-Browne-Sugawara [18]. To test a five-factor model, assuming the null hypothesis of a mean square error of approximation (RMSEA) from 0.05 to 0.08, a statistical power of 0.80, an alpha value of 0.05, with 205 df, a minimum sample size of 225 was required. This sample was over-estimated by 20% to cover possible losses. These calculations were carried out using STATISTICA 12 (Dell Software, Tulsa, OK).

Instruments

A sociodemographic questionnaire was used to collect personal data of the patient living with T2DM related to gender, age, marital status, educational level and employment situation. Besides, T2DM related questionnaire was used in order to know age of diagnosis, disease duration, and type and duration of treatment for T2DM. As in other validation studies carried out in Spain and UK [14] in addition to sociodemographic and disease related data, the following self-reported scales were also collected:

- **LW-T2DM** [15] scale focused to measure living with LTC. It is 26 items distributed in the following 5 dimensions: acceptance (4 items), coping (7 items), self-management (4 items), integration (5 items) and adjustment (6 items). It is a five-point Likert-scale ranging from 0 (nothing/never) to 4 (much/always) (except for the "acceptance dimension", in which the score is reversed). The final score ranges from 0 and 104 (higher scores better living with the LTC). The instrument is available as additional file 1 in Spanish and English language.
- **The Duke-UNC Functional Social Support Questionnaire (DUFSS)** [19,20] was used to evaluate social support of the patients’ from their perspective. It is an 8-items that evaluates different dimensions of
social support as confidant, affective and instrumental support. The score for each item varies from 1 (much less than I would like) to 5 (as much as I would like).

- *The World Health Organization Quality of Life Instrument-Brief (WHOQOL-BREF)* [21] was used to measure the quality of life of people living with T2DM. The WHOQOL-BREF is comprised by 24-items that evaluates physical health, psychological health, social relationships, and environment. Item response options range from 1 (very dissatisfied) to 5 (very satisfied/very good quality of life).

- *The modified version of the Satisfaction with Life Scale* [22] is a to evaluate satisfaction overall with life (item 1) and in regard to other five areas: physical, psychological wellbeing, social relations, leisure, and financial situation. Each item scores from 0 (unsatisfied) to 10 (totally satisfied).

- *The Patient Based Global Impression of Severity Scale (PGIS)* [23] was used to evaluate the patient global impression of severity of the T2DM. It is a six-point Likert-scale ranging from 0 (not ill at all) to 5 (extremely ill) according to the patient.

For this validation study, the Spanish version of the scales was used.

**Data collection**

Data collection was carried out between May 2018 and June 2019. The potential participants (people living with T2DM) filled in the scales during the consult with the endocrinology, GP, nurse specialist or primary care nurse. To ensure homogeneity and reproducibility of the procedure of data collection a standardized protocol was established with the following steps: explaining the research study; asking about doubts; reading out load instructions of the scales and its answer options; writing a check marc in the answer chosen by the patient; reading out load instructions of self-reported scales and giving participants time to complete it. The median time to complete all the measures was approximately 30-40 minutes.

Data collection related to test-retest was also protocolized to minimize potential random errors.

Patients were asked to answer a second time to the LW-T2DM at home. The LW-T2DM was in an envelope with seal and the research postal direction in order to complete the questionnaire and send it in an easy and free way to the researchers. A minimum sample of 50 subjects and a time span of 7 to 10 days for the retest was planned.

**Data analysis**

Descriptive statistics (central tendency measures, proportions) were used to determine the sociodemographic and T2DM characteristics. Main data were ordinal or did not fit normal distribution. Therefore, non-parametric statistics were used.
For the following psychometric properties were tested in this LW-T2DM validation study:

Feasibility and acceptability. Quality of data was considered satisfactory if 95% of the data were computable. The limit for missing data was <5% [24]. Floor and ceiling effect were deemed acceptable if they were <15% [25] and the skewness was expected between -1 to +1 [26].

Internal consistency was tested by Cronbach’s alpha coefficient (criterion value >0.70) [27], item-total correlation (corrected for overlap; criterion value, r_s ≥ 0.30) [28], inter-item correlation (criterion value, r ≥ 0.20 and ≤ 0.75) [29], and item homogeneity (criterion value > 0.30) [30].

Reproducibility (test-retest) was determined using weighted kappa (with quadratic weights) for items (standard: >0.41 moderate) [31] and intraclass correlation coefficient (one way, random effect; ICC) for domains and total score. Values ≥ 0.60 were considered acceptable [32].

Precision was estimated by means of the standard error of measurement (SEM = SD_pooled * √[1−r_xx]), where SD_pooled = √[(SD^4 + SD^4)/2] and r_xx was the ICC of the test-retest. A SEM value < ½SD_pooled was used as criterion of acceptable precision [33,34].

Construct validity. Confirmatory factor analysis (CFA) was applied to corroborate the original 5-factor matrix of the instrument, using the following parameters of indices of good fit: (CMIN/df) less than 5 (preferably less than 3), RMSEA less than 0.08 with the respective 90% CI, comparative fit index (CFI) of more than 0.90, and goodness-of-fit index (GFI) of more than 0.90 [35]. For convergent validity, and according to a previous study of the scale in patients with Parkinson’s disease [14], a moderate (r_s ≥ 0.35-0.50) or strong relationship (r_s > 0.50) [36] was hypothesized between LW-T2DM and DUFSS, SLS-6, and WHOQOL-BREF, and a weak/moderate association with other variables of the study, as age, T2DM duration or treatment. Spearman rank correlation coefficients were obtained to this purpose.

Internal validity, defined as the inter-correlations between the LW-T2DM dimensions (standard, r_s = 0.30-0.70) [30] and known-groups validity for gender, treatment and PGIS scores were determined. Mann-Whitney and Kruskal-Wallis tests were used for groups comparison.

**COSMIN assessment**

The COSMIN Checklist (COnsensus-based Stanard s for the selection of health Measurements INstruments) and its extension for content validity, were used for assessing the final measurement properties of the instrument and the methodology [37,38].

**Results**

582 people living with T2DM from Spain and Colombia were included in this first validation study, where the 52.6% of the sample were females with an average age of 64.15 (SD=2.18). The 57.5% were married,
the 60.3% present primary studies showing a basic educational level and the 30% were actively working full time at the moment of the study. The mean age of T2DM duration was 10.25 (SD=9.51) and the mean age with treatment 7.86 (SD=7.80) (Table 1).

(LOCATION OF TABLE 1)

Results related to data quality showed the scale had 6 missing data. There were 2 missing data in Domain 2. Coping, one missing data in Domain 3. Self-management, and 3 missing data in Domain 5. Adjustment. Regarding to acceptability, floor and ceiling effects for the total score ranged between 0.2% and 1.7% respectively. Domains and total score of the LW-T2DM did not show skewness.

Results related to internal consistency of the LW-T2DM showed that Cronbach's alpha was 0.90 for the total scale and for the domains ranged between 0.71 (Domain 3. Self-management) and 0.82 (Domains 1. Acceptance and 5. Adjustment). Item homogeneity ranged between 0.36 (Domain 4. Integration) and 0.53 (Domain 1. Acceptance). As it is showed in Table 2, all corrected item-total correlations were higher than established standard value.

(LOCATION OF TABLE 2)

Regarding the reproducibility of the LW-T2DM (test-retest), this analysis was carried out in 135 patients living with T2DM. The ICC for the total scale was 0.96 and for all domains over 0.90 (Table 3). For individual items, weighted kappa ranged between 0.66 (item 24) and 0.88 (items 22).

SEM was 3.34 (<½SD=8.52) for the total score of the scale and for the domains range from 0.92 to 1.52 (see Table 3).

(LOCATION OF TABLE 3)

The CFA supported the original 5-dimension model with 26 items. However, after analyzing residual errors in the standardized matrix of residual covariance, a final structure with 5 factor and 23 items showed better fit. Good indices were obtained: CMIN/df= 3.11; goodness of fit index= 0.91; comparative fit index= 0.91 and root mean square error of approximation = 0.06 (90% confidence interval, 0.06-0.07) (Figure 2). Cronbach's alpha of this 23-item scale ranged 0.71 (Self-management) to 0.83 (Adjustment) for domains, and was 0.89 for the total score.

(LOCATION OF FIGURE 2)

Related to convergent validity, the LW-T2DM presented strong relationship with DUFSS ($r_s=0.56$), with SLS-6 ($r_s=0.50$) and with Domain 2 of WHOQOL-BREF related to psychological health of the person ($r_s=0.51$). Besides, the LW-T2DM presented moderate correlations with all items of the SLS-6 and Domains 3 and 4 of the WHOQOL-BREF related to social relationships and environment, respectively. Weak correlation was found with T2DM duration and physical health of the patient (see Table 3). According to internal validity, domains inter-correlated from 0.09 (Acceptance with Coping) to 0.65 (Self-
management and Integration). See Table 3 for further detail. In relation to known-group validity, results showed that total scores were significantly different for gender (higher in women) and for PGIS (see Table 4).

(CLOCATION OF TABLE 4)

**COSMIN results**

Five psychometric properties are addressed in the LW-T2DM scale (Boxes A-E of the COSMIN checklist). The instrument obtains acceptable results for internal consistency, measurement error, reliability and structural (construct) validity. The content validity lacked information from patients and healthcare professionals. This shortcoming is reflected in the COSMIN extension on the evaluation of the development quality of the Patient Reported Outcome (PRO) (a full description is available as Additional File 2).

**Discussion**

The aim of this study is to validate the original EC-PC scale for persons with DM, obtaining an instrument (LW-T2DM) to measure how this population lives with the disease, with study outcomes that are useful both for researchers and in clinical practice.

Members of the research team have been working for several years to best define the concept of “living with chronic illness”. For this purpose, an in-depth conceptual analysis was first performed [6], reviewing the literature on this question and making use of Rodgers’ method of evolutionary concept analysis [5]. Before the psychometric evaluation, the questionnaire was piloted in various populations of persons with at least one chronic disease (including T2DM), to determine its viability and acceptability [15]. Many experts in the field consider this practice essential to ensure that the questionnaire items really address the construct that is to be measured [39].

In the present study, the non-response rate was less than 5% for all dimensions; there was no floor effect and in relation to the ceiling effect, only the 15% limit was exceeded, and that very slightly, for the “acceptance” dimension. These data suggest that, a priori, the scale provides reasonable acceptability [25].

LW-T2DM has excellent internal consistency (Cronbach’s alpha = 0.90) both overall and for each dimension, always remaining within the recommended limits, which suggests there is no redundancy in the content of the questions [40]. Similarly, the questionnaire presents high reliability in the sub-sample selected for the retest, comfortably surpassing the minimum levels recommended (ICC >0.70) [40] despite its significant extension, with 26 items. These findings suggest that LW-T2DM is a parsimonious instrument, measuring the intended aspects of the question with the fewest items possible, a quality that is highly desirable [41].
The CFA supported the original structure of the validated questionnaire in Parkinson's disease [14] although with 3 items less. All latent variables have high covariance except the acceptance dimension (0.06-0.32), this could be due to Acceptance of disease is always the first process necessary to achieve a positive living with the condition, because only when the person has accepted his/her illness, can move on to another processes [6]. In this sense, results emerged in other studies [6,14,15] showed that Acceptance is an internal, illness-independent, process through which the patient recognises and assumes the reality. This suggests the need for further research to elucidate the final configuration of the scale, using a robust validation methodology such as Rasch analysis [42].

Finally, the instrument is precise and correlates positively, at least to a moderate degree, with the existence of social support and with each of the subdimensions of the scales measuring satisfaction and quality of life. The correlation data are similar to those reported for the population with Parkinson's disease [14], showing that the questionnaire measures these cross-sectional constructs in a similar way in each of these chronic conditions. However, we must consider this aspect with caution, because the measurement invariance between groups has not yet been established.

Application of the LW-T2DM scale reveals significant differences according to the severity of the condition; thus, patients who are assigned higher scores (reflecting better coexistence with the disease) tend to be those who are less severely affected. Moreover, these scores are generally higher than those obtained by persons with Parkinson's disease, suggesting that living with T2DM is more tolerable. Differences by gender were also obtained, with higher scores for women. This finding differs from that produced by the pilot study, although this preliminary work included a population with other chronic diseases (COPD, HF or osteoarthritis) [15]. Other studies have shown that women with T2DM are at greater risk than men of psychosocial maladjustment, a poorer cardiovascular profile and/or non-compliance with treatment goals [43,44]. These outcomes are not consistent with our findings and further research is needed to clarify the question.

From a conceptual standpoint, the LW-T2DM scale has similarities with constructs addressed by other theoretical models. Thus, dimensions such as self-management or coping bear an important relationship with Bandura's concept of self-efficacy [45], which is widely used by other instruments in psychosocial approaches to chronic diseases [46,47]. Other dimensions, such as integration or adaptation, are closely linked to the notion of perceived control, introduced by Ajzen in his Theory of Planned Behaviour (TPB) [48]. The instrument also correlates very reasonably with social support, a concept also introduced in the TPB as the subjective norm (perceptions of the impact of third parties – such as family, friends or healthcare professionals – on whether or not the conduct in question takes place). The use of a conceptual model to underpin the LW-T2DM instrument enables the analyst to explain inductively how events happen and to suggest practical solutions to the problems encountered.

At the clinical level, the value of the instrument lies in its explanatory capacity, reflecting how a person with T2DM lives with the disease and thus allowing professionals to focus on the most troublesome aspects. This role is especially significant because healthcare professionals commonly express
frustration at not achieving the expected results from treatment and recommendations. On the other hand, many patients believe their healthcare is not sufficiently individualised [49]. Prior analyses of patients with Parkinson's disease have shown that social support, followed by satisfaction with life and by socioeconomic status, are the only factors relevant to the patient's coexistence with the disease [50]. If these factors were equally influential with respect to T2DM, we would be facing a scenario in which social factors exerted significant influence on health conditions and should be taken into account when socio-health policies are designed and applied.

Although the present study has been performed with all possible rigour, it is subject to certain limitations. According to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), for an instrument to present content validity, it must obtain information derived from what is already known on the subject, from the reference population and from healthcare providers [51]. While LW-T2DM is based on an important conceptual analysis of published research, the findings have not been triangulated with information obtained by qualitative techniques (via focus groups, cognitive interviews, the Delphi method, etc.), as described in the relevant section of the COSMIN checklist (Additional File 2). Furthermore, due to the innovative nature of the concept, LW-T2DM lacks a gold standard with which to verify its criteria validity. However, other instruments have been proposed to evaluate psychosocial aspects of diabetes, such as the Problem Areas in Diabetes (PAID) [52] and the Diabetes Empowerment Scale [53]. Although the approach they take is different from our own, it might be useful to analyse their possible correlations with LW-T2DM. Finally, due to the intrinsic nature of the present research, the question of sensitivity to change has not been evaluated.

**Conclusions**

LW-T2DM is a valid, reliable and precise instrument for assessing the question of living with T2DM. Additional research is needed to identify the factors that specifically impact on the concept of “living with” this disease. In addition, more extensive analyses should be made of the construct under study, by robust methods such as evaluating its factor structure by means of structural equations.

**List Of Abbreviations**

T2DM: Type 2 Diabetes Mellitus; COSMIN: COnsensus-based Standards for the selection of health Measurement INstruments; DUFFS: Duke-UNC Functional Social Support Scale; WHOQOL-BREF: World Health Organization Quality of Life Instrument-Brief Scale; SLS-6: Satisfaction with Life Scale; PGIS: Patient Based Global Impression of Severity Scale; LW-T2DM: Living With Type 2 Diabetes Mellitus Scale; IDF: International Diabetes Federation; MLHFQ: Minnesota Living with Heart Failure Questionnaire; LCOPD: Living with Chronic Obstructive Pulmonary Disease questionnaire; CPAQ: Chronic Pain Acceptance Questionnaire; DSMQ: Diabetes Self-Management Questionnaire; PAIS: Psychosocial Adjustment to Illness Scale; EC-PC: Escala de Convivencia con un Proceso Crónico (in spanish); LTC: long term condition; GP: General Practitioner; ICC: intraclass correlation coefficient; SEM: standard error of measurement; SD: standard desviation; PRO: Patient Reported Outcome; HF: heart failure, CPOD: chronic
obstructive pulmonary disease; TPB: Theory of Planned Behavior; PD: Parkinson Disease; ISPOR: International Society for Pharmacoeconomics and Outcomes Research; PAID: Problem Areas in Diabetes Scale.

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the Ethic Committee of University of Navarre in Spain (reference 2017.099) and the Ethic Committee of University of La Sabana in Colombia (reference 013). Besides, this study ensured the compliance of the Declaration of Helsinki rules and the principles of Law 14/2007 on Biomedical Research and Law 15/1999 on Protection of Personal Data. All participants gave their signed consent to participate in a voluntary way in the study without any compensation for this. after receiving the pertinent verbal and written information. All data and information related to the participant’s identity was handled in full confidential way throughout the research process by the principal investigator.

**Consent for publication**

Not applicable

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests

**Funding**

This study has been funded by the Ministry of Science, Innovation and University of the Spanish Government (FEDER/Ministerio de Ciencia, Innovación y Universidades – Agencia Estatal de Investigación/ Proyecto (CSO2017-82691-R)).

**Authors' contributions**

JC-B, CR-B and LA have made substantial contribution to the design of the work, conception, acquisition, analysis and interpretation of data and drafted the work. He has also approved the submitted version and agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work. DP-M, ET, GC, AF-R, SC, and MA have done the acquisition of the data, have approved the submitted version and have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work.
Acknowledgements

Not applicable

References

1. WHO. Global Health Observatory (GHO) data: Life expectancy. https://www.who.int/gho/mortality_burden_disease/life_tables/situation_trends/en/ (2016). Accessed 02 Jun 2020.

2. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice. 2018;138:271-81.

3. Wu H, Eggleston KN, Zhong J, Hu R, Wang C, Xie K, et al. How do type 2 diabetes mellitus (T2DM)-related complications and socioeconomic factors impact direct medical costs? A cross-sectional study in rural Southeast China. BMJ Open. 2018;8(11):e020647:1-11.

4. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221-8.

5. Rodgers BL. Concept analysis: an evolutionary view. In Concept Development in Nursing. 2000. WB Saunders Company, Philadelphia, US, PA, pp. 77–102.

6. Ambrosio L, Senosiain García JM, Riverol Fernández M, Anaut Bravo S, Díaz De Cerio Ayesa S, Ursúa Sesma ME, et al. Living with chronic illness in adults: a concept analysis. J Clin Nurs. 2015;24(17-18):2357-67.

7. Kularatna S, Senanayake S, Chen G, Parsonage W. Mapping the Minnesota living with heart failure questionnaire (MLHFQ) to EQ-5D-5L in patients with heart failure. Health Qual Life Outcomes. 2020;18(1):115.

8. McKenna SP, Meads DM, Doward LC, Twiss J, Pokrzywinski R, Revicki D, et al. Development and validation of the living with chronic obstructive pulmonary disease questionnaire. Qual Life Res. 2011;20(7):1043-52.

9. McCracken LM, Vowles KE, Eccleston C. Acceptance of chronic pain: component analysis and a revised assessment method. Pain. 2004;107(1-2):159-66.

10. Carver CS. You want to measure coping but your protocol’s too long: consider the brief COPE. Int J Behav Med. 1997;4(1):92-100.

11. Schmitt A, Gahr A, Hermanns N, Kulzer B, Huber J, Haak T. The Diabetes Self-Management Questionnaire (DSMQ): development and evaluation of an instrument to assess diabetes self-care activities associated with glycaemic control. Health Qual Life Outcomes. 2013;11(138):1-14.

12. Rodrigue JR, Kanasky WF, Jackson SI, Perri MG. The Psychosocial Adjustment to Illness Scale–Self-Report: factor structure and item stability. Psychol Assess. 2000;12(4):409-13.
13. Ambrosio L, Portillo MC. Tools to assess living with a chronic illness: A systematic review. Enfermería Clínica (English Edition). 2018;28(4):220–229.

14. Ambrosio L, Portillo MC, Rodríguez-Blázquez C, Rodriguez-Violante M, Castrillo JCM, Arillo VC, et al. Living with chronic illness scale: international validation of a new self-report measure in Parkinson’s disease. NPJ Parkinsons Dis. 2016;2(16022): 1-6.

15. Ambrosio L, Navarta-Sánchez MV, Meneses A, Rodríguez-Blázquez C. Living with Chronic Illness Scale: Pilot study in patients with several chronic diseases. Aten Primaria. 2020;52(3):142-50.

16. Bowling A. Research Methods In Health: Investigating Health And Health Services. 4th ed. Open Berkshire: University Press; 2014.

17. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373-9.

18. MacCallum R, Lee T, Browne MW. The Issue of Isopower in Power Analysis for Tests of Structural Equation Models. Structural Equation Modeling: A Multidisciplinary Journal. 2010;17(1):23-41.

19. Ayala A, Rodríguez-Blázquez C, Frades-Payo B, Forjaz MJ, Martínez-Martín P, Fernández-Mayoralas G, et al. Psychometric properties of the Functional Social Support Questionnaire and the Loneliness Scale in non-institutionalized older adults in Spain. 2012;26(4):317-24.

20. Broadhead WE, Gehlbach SH, de Gruy FV, Kaplan BH. The Duke-UNC Functional Social Support Questionnaire. Measurement of social support in family medicine patients. Med Care. 1988;26(7):709-23.

21. Group, T. W. The World Health Organization quality of life assessment (WHOQOL): development and general psychometric properties. Social science & medicine. 1998;46(12): 1569-1585.

22. Mazaheri M, Theuns P. A study of how satisfaction and dissatisfaction with life overall relate to satisfaction and dissatisfaction in specific life domains. Patient Reported Outcomes Newsletter. 2006;37:24.

23. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Mental Health. Psychopharmacology Research Branch. 1976;217–22.

24. Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess. 2005;9(10):1-93, iii-iv.

25. McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res. 1995;4(4):293-307.

26. van der Linden F a. H, Kragt JJ, Klein M, van der Ploeg HM, Polman CH, Uitdehaag BMJ. Psychometric evaluation of the multiple sclerosis impact scale (MSIS-29) for proxy use. J Neurol Neurosurg Psychiatry. 2005;76(12):1677-81.

27. Aaronson N, Alonso J, Burnam A, Lohr KN, Patrick DL, Perrin E, et al. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res. 2002;11(3):193-205.
28. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. Health Technol Assess. 2004;8(9):iii, 1-48.

29. Piedmont, R. L. Inter-item correlations. Encyclopedia of quality of life and well-being research. 2014;3303-4.

30. Eisen M, Ware Jr JE, Donald CA, Brook RH. Measuring components of children's health status. Medical care. 1979;902–21.

31. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;159–74.

32. Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychological assessment. 1994;6(4):284.

33. Clark LA, Watson D. Constructing validity: Basic issues in objective scale development. 2016 In A. E. Kazdin, editors. American Psychological Association. 2016. p. 187–203.

34. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582-92.

35. Bollen KA, Long JS. Testing structural equation models. https://us.sagepub.com/en-us/nam/testing-structural-equation-models/book3893. Accessed September 14, 2020.

36. Feeny D, Farris K, Côté I, Johnson JA, Tsuyuki RT, Eng K. A cohort study found the RAND-12 and Health Utilities Index Mark 3 demonstrated construct validity in high-risk primary care patients. J Clin Epidemiol. 2005;58(2):138-41.

37. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol. 2010;63(7):737-45.

38. Terwee CB, Prinsen C a. C, Chiarotto A, Westerman MJ, Patrick DL, Alonso J, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Qual Life Res. 2018;27(5):1159-70.

39. Brod M, Tesler LE, Christensen TL. Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res. 2009;1263-78.

40. Terwee CB, Bot SDM, de Boer MR, van der Windt DAWM, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;34-42.

41. Rhodes RE, Plotnikoff RC, Spence JC. Creating parsimony at the expense of precision? Conceptual and applied issues of aggregating belief-based constructs in physical activity research. Health Education Research. 2004;392-405.

42. Ambrosio L, Rodriguez-Blazquez C, Ayala A, Forjaz MJ. Rasch analysis of the Living with Chronic Illness Scale in Parkinson's disease. BMC Neurol. 2020; 20(346):1-7.

43. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev. 2016;37(3):278-316.
44. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, et al. Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study. J Intern Med. 2013;274(2):176-91.

45. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychological review. 1977;84(2):191–215.

46. Rapley P, Passmore A, Phillips M. Review of the psychometric properties of the Diabetes Self-Efficacy Scale: Australian longitudinal study. Nursing & health sciences. 2003;5(4), 289-297.

47. Sturt J, Hearnshaw H, Wakelin M. Validity and reliability of the DMSES UK: a measure of self-efficacy for type 2 diabetes self-management. Primary Health Care Research & Development. 2010;374–81.

48. Ajzen I. The theory of planned behaviour: Reactions and reflections. Psychology & Health. 2011;26(9):1113-27.

49. Rushforth B, McCrorie C, Glidewell L, Midgley E, Foy R. Barriers to effective management of type 2 diabetes in primary care: qualitative systematic review. Br J Gen Pract. 2016;66(643):e114-127.

50. Ambrosio L, Portillo MC, Rodriguez-Blazquez C, Rojo JM, Martinez-Martin P, Group E-PV, et al. Influencing factors when living with Parkinson’s disease: A cross-sectional study. J Clin Nurs. 2019;28(17-18):3168–76.

51. Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD. Use of Existing Patient-Reported Outcome (PRO) Instruments and Their Modification: The ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report. Value in Health. 2009;12(8):1075–83.

52. Beléndez M, Hernández-Mijares A, Marco J, Domínguez JR, Pomares FJ. Validation of the Spanish version of the Problem Areas in Diabetes (PAID-SP) Scale. Diabetes Res Clin Pract. 2014;106(3):e93-5.

53. Balcázar-Nava P, Gurrola-Peña GM, Moysén-Chimal A, Uracid-Velarde S, Garay-López JC, Velasco-Fuentes MC, et al. Análisis de las propiedades psicométricas de la diabetes empowerment scale (des-if-s) en español. 2016;13(2):95-104.

Tables

Table 1. Characteristics of sample
### Sociodemographic characteristics

|                                | Total sample | Subsample Spain | Subsample Colombia | P value |
|--------------------------------|--------------|-----------------|--------------------|---------|
|                                | N=582        | N=248           | N=334              |         |
| Female (%)                     | 306 (52.6)   | 95 (38.3)       | 211 (63.2)         | <0.001a |
| Marital Status (%)             |              |                 |                    |         |
| Single                         | 87 (15.0)    | 34 (13.9)       | 53 (15.9)          | <0.001a |
| Married                        | 333 (57.5)   | 165 (67.3)      | 168 (50.3)         |         |
| Widower                        | 93 (16.1)    | 31 (12.7)       | 62 (18.6)          |         |
| Other                          | 66 (11.4)    | 15 (6.1)        | 51 (15.3)          |         |
| Occupation (%)                 |              |                 |                    | <0.001a |
| Active                         | 174 (29.9)   | 79 (32.0)       | 95 (28.4)          |         |
| Homemaker                      | 159 (27.4)   | 29 (11.7)       | 130 (38.9)         |         |
| Retired                        | 121 (20.8)   | 116 (47.0)      | 5 (1.5)            |         |
| Other                          | 127 (21.9)   | 23 (9.3)        | 104 (31.1)         |         |
| Education (%)                  |              |                 |                    | 0.577a  |
| None                           | 11 (1.9)     | 3 (1.2)         | 8 (2.4)            |         |
| Primary                        | 350 (60.3)   | 144 (58.5)      | 206 (61.7)         |         |
| High school                    | 134 (23.1)   | 61 (24.8)       | 73 (21.9)          |         |
| University                     | 85 (14.7)    | 38 (15.4)       | 47 (14.1)          |         |
| Insulin therapy (%)            | 268 (51.5)   | 69 (37.1)       | 199 (59.6)         | <0.001a |
| Age (mean ± SD)                | 64.15 (12.18)| 65.27 (11.32)  | 63.32 (12.74)      | 0.056b  |
| Time since diagnosis*          | 10.25 (9.51) | 11.49 (10.54)  | 9.34 (8.56)        | 0.007b  |
| Time with insulin therapy*     | 4.04 (7.81)  | 9.45 (12.16)    | 2.92 (6.01)        | <0.001b |

P value between subsamples; SD, Standar Desviation.

a Chi test. b Mann-Whitney-Wilcoxon test. * Years.

**Table 2.** Feasibility/Acceptability, reliability and precision of the LW-T2DM
| Domain 1. Acceptance | Domain 2. Coping | Domain 3. Self-management | Domain 4. Integration | Domain 5. Adjustment | Total score |
|---------------------|-----------------|--------------------------|----------------------|---------------------|-------------|
| Mean (SD)           |                 |                          |                      |                     |             |
| 11.53 (3.74)        | 18.80 (5.56)    | 11.00 (3.37)             | 14.82 (3.66)         | 15.35 (5.45)        | 71.53 (16.45) |

Data Quality (% fully computable data)

| Floor effect (%) | Ceiling effect (%) | Skewness | Cronbach’s alpha | Item-total correlation | Item homogeneity | Reproducibility (ICC) | Precision (SEM) |
|------------------|--------------------|----------|------------------|------------------------|------------------|----------------------|-----------------|
| 1.0              | 19.8               | -0.78    | 0.82              | 0.36-0.67              | 0.53             | 0.93                 | 0.92            |
| 0.5              | 6.2                | -0.47    | 0.77              | 0.21-0.50              | 0.33             | 0.93                 | 1.52            |
| 0.7              | 10.8               | -0.54    | 0.71              | 0.32-0.53              | 0.40             | 0.93                 | 1.05            |
| 0.2              | 13.2               | -0.60    | 0.72              | 0.16-0.58              | 0.36             | 0.91                 | 1.05            |
| 0.5              | 9.7                | -0.24    | 0.82              | 0.16-0.60              | 0.42             | 0.91                 | 1.00            |
| 0.2              | 1.7                | -0.34    | 0.90              |                        |                  | 0.96                 | 3.34            |

Skewness: -0.78; -0.47; -0.54; -0.60; -0.24; -0.34
Cronbach’s alpha: 0.82; 0.77; 0.71; 0.72; 0.82; 0.90
Item-total correlation: 0.36-0.67; 0.21-0.50; 0.32-0.53; 0.16-0.58; 0.16-0.60
Item homogeneity: 0.53; 0.33; 0.40; 0.36; 0.42
Reproducibility (ICC): 0.93; 0.93; 0.90; 0.91; 0.96
Precision (SEM): 0.92; 1.52; 1.05; 1.01; 1.08; 3.34
Precision (1/2 SD): (1.74); (2.88); (1.65); (1.68); (2.71); (8.52)

LW-T2DM: Living with Type 2 Diabetes Mellitus.

SD: standard deviation; ICC: intraclass correlation coefficient; SEM: standard error of measurement = SD_{pooled} * √(1-ICC).

**Table 3.** Convergent validity and internal validity of LW-T2DM
**Domain 1. Acceptance**

| Convergent validity | Age | Age onset T2DM | T2DM duration | WHOQOL - Physical health | WHOQOL - Psychological | WHOQOL - Social relationships | WHOQOL - Environment | DUFSS | Satisfaction With Life | Satisfaction - physical health | Satisfaction - well-being | Satisfaction - social relations | Satisfaction - leisure | Satisfaction - financial situation |
|---------------------|-----|----------------|---------------|--------------------------|------------------------|---------------------------|---------------------------|-------|------------------------|-------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------------------------|
|                     | 0.14** | 0.14** | 0.09* | 0.22** | 0.23** | 0.19** | 0.22** | 0.18** | 0.28** | 0.24** | 0.26** | 0.29** | 0.26** | 0.19** |
|                     | -0.04 | -0.1* | -0.08 | 0.22** | 0.44** | 0.31** | 0.32** | 0.48** | 0.34** | 0.36** | 0.25** | 0.33** | 0.31** | 0.35** |
|                     | -0.02 | -0.02 | -0.01 | 0.21** | 0.40** | 0.27** | 0.34** | 0.49** | 0.46** | 0.47** | 0.24** | 0.31** | 0.33** | 0.39** |
|                     | 0.05 | 0.06 | -0.02 | 0.31** | 0.48** | 0.40** | 0.49** | 0.49** | 0.47** | 0.47** | 0.32** | 0.39** | 0.39** | 0.41** |
|                     | -0.05 | -0.02 | -0.04 | 0.24** | 0.45** | 0.32** | 0.34** | 0.47** | 0.40** | 0.40** | 0.35** | 0.35** | 0.31** | 0.29** |
|                     | 0.02 | 0.04 | -0.10 | 0.30** | 0.51** | 0.38** | 0.43** | 0.56** | 0.44** | 0.38** | 0.38** | 0.45** | 0.48** | 0.41** |

**Field validity**

| Internal validity | Coping | Self-management | Integration | Adjustment |
|-------------------|--------|-----------------|-------------|------------|
|                   | 0.09*  | 0.17**          | 0.24**      | 0.13**     |
|                   | --     | --              | 0.62**      | 0.62**     |
|                   | --     | --              | 0.56**      | 0.56**     |
|                   | --     | --              | --          | --         |
|                   | --     | --              | --          | --         |

**Table 4. Known-group validity**

| Categories                  | LW-T2DM total | P value |
|-----------------------------|---------------|---------|
| Sex                         |               | <0.001  |
| Men                         | 68.65 (16.21) |         |
| Women                       | 74.12 (16.28) |         |
| Treatment for T2DM (insulin)|               | 0.09    |
| Yes                         | 72.45 (16.49) |         |
| No                          | 69.75 (16.70) |         |
| PGIS-based severity levels  |               | <0.001  |
| None                        | 75.70 (17.00) |         |
| Mild                        | 71.31 (15.65) |         |
| Moderate                    | 71.52 (15.61) |         |
| Severe                      | 64.27 (17.10) |         |

Mean (standard deviation).

LW-T2DM: Living with Type 2 Diabetes Mellitus.